<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prebiotics and probiotics for treatment of allergic disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prebiotics and probiotics for treatment of allergic disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prebiotics and probiotics for treatment of allergic disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan Prescott, MBBS, FRACP, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christina West, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott H Sicherer, MD, FAAAAI</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11508576"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The rapid increase in immune-mediated disorders such as allergic disease is strongly linked to reduced early microbial exposure [<a href="#rid1">1,2</a>]. The gut microbiota represents the greatest microbial exposure by far and is central to the development of immune regulation. The specific composition of the gut microbiota may affect the risk of developing allergic disease [<a href="#rid3">3</a>]. This finding provided the foundation for intervention studies designed to modify gut microbial composition for the treatment of allergic disease. The effects of beneficial bacteria (probiotics) or resistant starches or fiber (prebiotics) that selectively stimulate a limited number of beneficial bacteria have been evaluated in allergy treatment studies.</p><p>This topic examines the evidence for prebiotics and probiotics in the treatment of allergic disease [<a href="#rid4">4-8</a>]. The evidence for prebiotics and probiotics in the prevention of allergic disease is presented separately. The definitions of prebiotics, probiotics, and synbiotics; proposed mechanisms of action; rationale for use in allergic disease; and side effects and safety are also discussed separately. (See  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease"</a>.)</p><p class="headingAnchor" id="H3550708502"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>Prebiotics are nondigestible carbohydrates that stimulate the growth and/or activity of beneficial colonic bacteria. Probiotics are live microorganisms that benefit the host. Synbiotics are a combination of prebiotics and probiotics. (See  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease", section on 'Definitions'</a>.)</p><p class="headingAnchor" id="H11508604"><span class="h1">CLINICAL TREATMENT STUDIES USING PREBIOTICS</span><span class="headingEndMark"> — </span>Randomized, controlled trials evaluating the effects of prebiotics for treatment of allergic disease are scarce, and further studies are needed before any conclusions can be drawn.</p><p>The effect of kestose, a fructo-fructooligosaccharide (FOS), was assessed in a trial that randomized 29 infants and children under three years of age with eczema to daily ingestion of kestose or maltose (placebo) for 12 weeks [<a href="#rid9">9</a>]. Median SCORAD (<strong>SCOR</strong>ing <strong>A</strong>topic <strong>D</strong>ermatitis) scores were significantly lower at 6 and 12 weeks in the prebiotic group compared with placebo. Another trial found no reduction in SCORAD in infants fed galacto-oligosaccharides (GOS) in a formula with hydrolyzed protein compared with the same formula without any addition [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H11508611"><span class="h1">CLINICAL TREATMENT STUDIES USING PROBIOTICS</span><span class="headingEndMark"> — </span>Initial meta-analyses suggest no benefit of oral probiotics in the treatment of eczema or asthma. One meta-analysis reported a beneficial effect of probiotics in the treatment of allergic rhinitis, but it was not conclusive, and further studies are needed.</p><p>Caution is advised when using probiotics in immunocompromised patients, including premature infants, due to an increased risk of adverse effects and, in rare cases, infection caused by fungal contamination [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H5938517"><span class="h2">Eczema</span><span class="headingEndMark"> — </span>There are a number of meta-analyses on using probiotics for eczema treatment [<a href="#rid5">5,13-18</a>]. Most have concluded that there is no consistent evidence that live oral probiotics are useful for the treatment of established eczema. Additional subgroup analyses according to evidence of allergen sensitization or eczema severity did not affect this conclusion. Subsequent trials have been consistent with these findings [<a href="#rid19">19</a>], although <em>Lactobacillus</em> strains appear to have benefits in some settings. A small trial reported reduced SCORAD (<strong>SCOR</strong>ing <strong>A</strong>topic <strong>D</strong>ermatitis) and improved quality-of-life measures in adults with eczema following 16 weeks of treatment with a <em>Lactobacillus salivarius</em> strain compared with placebo [<a href="#rid20">20</a>], and one meta-analysis reported that the therapeutic effects of probiotics in eczema treatment showed differences according to country and geographic region [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/1730.html" rel="external">"Treatment of atopic dermatitis (eczema)", section on 'Probiotics'</a>.)</p><p>There are problems with the quality of some studies. In addition, the high degree of heterogeneity, which includes marked differences in probiotic preparations, study populations, and outcome measures, hampers direct comparison of studies. <em>Lactobacillus rhamnosus</em> GG (LGG) is the most extensively studied strain in the treatment of atopic dermatitis, with both positive and negative results [<a href="#rid21">21-27</a>]. Three other probiotic strains, <em>Lactobacillus fermentum</em> VR1-003PCC, <em>Lactobacillus sakei</em> KCTC 10755BP, and <em>Lactobacillus plantarum</em> CJLP133, have reduced SCORAD scores significantly in more limited trials [<a href="#rid28">28-30</a>]. Preliminary data suggest that dead probiotic microorganisms given orally or administered topically may be effective in the treatment of eczema, but further trials are needed [<a href="#rid31">31-33</a>].</p><p>The effect of probiotics in the treatment of allergic disease was first studied in infants with eczema, with or without associated food allergy. The initial study targeted infants with eczema and cow's milk allergy [<a href="#rid27">27</a>]. In that study, 27 infants were randomized to extensively hydrolyzed whey formula (eHF) with or without LGG for four weeks. The SCORAD score reductions were similar in the LGG and control groups.</p><p>In another early study by the same group, infants fed eHF with added LGG or <em>Bifidobacterium lactis</em> had a more rapid improvement of eczema compared with placebo (eHF alone) [<a href="#rid21">21</a>]. In contrast, there was no effect of LGG administration on eczema in a study with a comparable design [<a href="#rid22">22</a>]. Other groups have reported no benefit of LGG on SCORAD, medication requirements [<a href="#rid23">23,24</a>], or subjective parameters [<a href="#rid23">23</a>].</p><p>Results from a larger study [<a href="#rid25">25</a>] suggested that immunoglobulin E (IgE) sensitized individuals might be more likely to benefit from probiotic treatment. In that study, there was a reduction in SCORAD scores in infants with IgE-associated eczema who had received LGG compared with placebo, even though there was no overall effect. These findings are consistent with another study that reported significant SCORAD improvement with probiotics in a subgroup of food-sensitized children, while there was no overall effect in the whole study population [<a href="#rid26">26</a>].</p><p>The definition of probiotics indicates that the microorganisms should be alive to exert their effects (see  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease", section on 'Definitions'</a>). However, there is some evidence that dead probiotic microorganisms may also exert beneficial effects [<a href="#rid31">31</a>]. In one trial, 60 children (1 to 12 years of age) with eczema were randomized to heat-inactivated <em>Lactobacillus acidophilus</em> L-92 or placebo for eight weeks [<a href="#rid32">32</a>]. Both groups showed an improvement in eczema severity (as assessed by the Atopic Dermatitis Area and Severity Index), but the improvement was greater in the group assigned to <em>L. acidophilus</em> L-92. In a study of 50 participants &gt;16 years of age with atopic dermatitis, intake of heat-killed <em>L. acidophilus</em> L-92 led to reduced severity of eczema using both objective and subjective assessments compared with a placebo group [<a href="#rid34">34</a>]. A much earlier study was also designed to compare the effect of viable or heat-inactivated LGG with a placebo in the treatment of eczema and cow's milk allergy [<a href="#rid35">35</a>]. However, this trial was terminated prematurely due to adverse effects (gastrointestinal symptoms) in the group of infants that received heat-inactivated LGG. Therefore, no firm conclusions can be drawn. Future research is needed to establish if inactivated microorganisms are effective in the treatment of eczema.</p><p>Most studies have used oral ingestion of probiotics, but there are limited studies on topical use. In one randomized trial, the topical application of a lysate of <em>Vitreoscilla filiformis</em>, a nonpathogenic gram-negative bacterium, led to a significant reduction in both SCORAD scores and cutaneous <em>Staphylococcus aureus</em> colonization compared with placebo [<a href="#rid33">33</a>]. These preliminary results need further validation.</p><p class="headingAnchor" id="H5938524"><span class="h2">Allergic rhinitis and asthma</span><span class="headingEndMark"> — </span>Most studies using probiotics in the treatment of respiratory allergic disease have evaluated the effects of probiotics in the treatment of allergic rhinitis in adolescents and adults with conflicting results. A few studies report that certain probiotic strains such as <em>Bifidobacterium longum</em> (BB536) [<a href="#rid36">36</a>], <em>Lactobacillus paracasei</em> Lp33 [<a href="#rid37">37</a>], and <em>L. acidophilus</em> L-92 [<a href="#rid38">38</a>] lessen symptoms of allergic rhinitis and improve quality of life, while there was no benefit of LGG [<a href="#rid39">39</a>] or <em>Lactobacillus casei</em> strain Shirota [<a href="#rid40">40</a>]. One study reported that symptoms of allergic rhinitis were alleviated after treatment with a multistrain probiotic mixture [<a href="#rid41">41</a>]. A meta-analysis including 15 studies reported a beneficial effect of probiotics treatment of allergic rhinitis with reduced symptom severity and increased quality of life [<a href="#rid42">42</a>], but it was not conclusive, and further studies are needed.</p><p>Meta-analyses have identified that marked heterogeneity among studies makes direct comparison difficult. Even though probiotics may improve symptoms and quality of life in patients with allergic rhinitis, evidence is still limited because of heterogeneity in study design and outcome measures [<a href="#rid43">43</a>]. A trial published after this meta-analysis reported that a probiotic combination of one <em>Lactobacillus</em> and two <em>Bifidobacterium</em> strains improved quality of life in adults with allergic rhinitis compared with placebo; however, there was no effect on IgE concentrations or regulatory T cell (Treg) percentages [<a href="#rid44">44</a>]. In addition, a trial in 63 children aged 7 to 12 years with confirmed house dust mite allergy and moderate-to-severe allergic rhinitis published after the first meta-analysis demonstrated that <a class="drug drug_general" data-topicid="9443" href="/d/drug information/9443.html" rel="external">levocetirizine</a> plus a <em>Lactobacillus johnsonii</em> strain was superior to levocetirizine alone for improving nasal peak expiratory flow [<a href="#rid45">45</a>]. One published study showed a benefit of <em>Lactobacillus gasseri</em> on objective airway measurements [<a href="#rid46">46</a>].</p><p>Allergic rhinitis often coexists with asthma. Therefore, a few studies have included subjects with both asthma and allergic rhinitis. One randomized trial of 187 preschool children with respiratory allergic disease (asthma and/or allergic rhinitis) evaluated the effects of long-term consumption of fermented milk with the addition of a <em>L. casei</em> strain compared with nonfermented milk (placebo) [<a href="#rid47">47</a>]. Episodes of rhinitis were fewer in the probiotic group during the 12-month intervention, but there was no reduction in episodes of asthma. However, it was not confirmed if the rhinitis episodes were of allergic or viral origin.</p><p>Another study randomized 118 children aged 6 to 12 years with mild-to-moderate persistent asthma and persistent allergic rhinitis to daily intake of <em>L. gasseri </em>or placebo for eight weeks [<a href="#rid46">46</a>]. Both groups reported a reduction in the clinical severity of asthma and allergic rhinitis following treatment, but the number of patients with an improved score was higher in the probiotic group. There was an increase in forced expiratory volume in the first second (FEV<sub>1</sub>), forced vital capacity (FVC), FEV<sub>1</sub>/FVC, and postbronchodilator FEV<sub>1 </sub>following five weeks of treatment in children receiving probiotics compared with placebo, demonstrating an effect on objective airway measurements. In adults with asthma, treatment for eight weeks with a probiotic mix led to reduced T helper type 2 (Th2) cells-associated interleukin (IL) 4 and improved FEV<sub>1</sub> and FVC [<a href="#rid48">48</a>]. However, a meta-analysis including 10 probiotic studies did not find any effect on objective airway measurements [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H11508618"><span class="h1">SYNBIOTICS FOR TREATMENT OF ALLERGIC DISEASE</span><span class="headingEndMark"> — </span>A few studies have used probiotics in combination with prebiotic oligosaccharides (synbiotics). One systematic review and meta-analysis examined six treatment studies and two prevention studies of synbiotics for atopic dermatitis [<a href="#rid50">50</a>]. The pooled change in SCORAD (<strong>SCOR</strong>ing <strong>A</strong>topic <strong>D</strong>ermatitis) scores at eight weeks was greater in the synbiotic group than then placebo group, an effect that was only significant in the subgroup analysis when mixed strains of bacteria were used and treated children were ≥1 year of age. In one of the included studies, for example, 90 children one to three years of age with moderate-to-severe atopic dermatitis were randomly assigned to daily intake of a synbiotic mixture with <em>L. acidophilus</em> DDS-1 and <em>B. lactis</em> UABLA-12 plus fructooligosaccharides (FOS) or placebo for eight weeks [<a href="#rid51">51</a>]. The decrease in SCORAD score was greater in the synbiotic compared with the placebo group.</p><p>In another trial, 90 infants under seven months of age with atopic dermatitis were randomized to receive an extensively hydrolyzed whey formula (eHF) with or without synbiotics (<em>Bifidobacterium breve</em> M-16V and a mixture of 90 percent galacto-oligosaccharides [GOS] and 10 percent FOS) for 12 weeks [<a href="#rid52">52</a>]. Overall, there was no difference in SCORAD improvement between the two groups, but the SCORAD improvement was significantly greater in the synbiotic group than the placebo group in the subgroup of infants with IgE-associated eczema. This is consistent with a few probiotic treatment studies that reported no overall effect but found a benefit in infants and children with evidence of IgE sensitization to foods [<a href="#rid25">25,26</a>].</p><p>One study has evaluated if synbiotics are superior to prebiotics alone [<a href="#rid53">53</a>]. In this trial, 60 children aged 2 to 14 years with moderate-to-severe eczema were randomized to synbiotics (<em>Lactobacillus salivarius</em> plus FOS) or FOS alone for eight weeks [<a href="#rid53">53</a>]. SCORAD scores following treatment were significantly lower in the synbiotic group compared with prebiotic therapy, in conjunction with a reduction in eosinophilic cationic protein (ECP) levels and frequency of medication use.</p><p>Synbiotics in the treatment of asthma were evaluated in a trial that randomized 29 adults with asthma and house dust mite allergy to synbiotics (<em>B. breve</em> M-16V and a mixture of 90 percent GOS and 10 percent FOS) or placebo for four weeks [<a href="#rid54">54</a>]. Peak expiratory flow and systemic T helper type 2 (Th2) cytokines were reduced in the synbiotic group compared with placebo, but there was no effect on bronchial inflammation. One study on persistent allergic rhinitis reported that synbiotics supplementation for four months reduced symptoms and IgE levels compared with placebo [<a href="#rid55">55</a>]. These results are preliminary and need confirmation in other clinical settings.</p><p class="headingAnchor" id="H11508632"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions</strong> – Prebiotics are nondigestible carbohydrates that stimulate the growth and/or activity of beneficial colonic bacteria. Probiotics are live microorganisms that benefit the host. Synbiotics are a combination of prebiotics and probiotics. (See  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease", section on 'Definitions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms of action and timing of use</strong> – There is evidence from animal models and in vitro studies that gut microbiota modulate immune programming, promote oral tolerance, and are important in inhibiting the development of the allergic phenotype. However, the therapeutic effect of prebiotics or probiotics may be reduced once colonization and the allergic phenotype are established compared with treatment at younger ages when there is greater plasticity. (See  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease", section on 'Rationale for prebiotics and probiotics in allergic disease'</a> and  <a class="medical medical_review" href="/d/html/13581.html" rel="external">"Prebiotics and probiotics for prevention of allergic disease", section on 'Proposed mechanisms'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Study limitations</strong> – There are several limitations that have hampered direct comparison of probiotic studies, including the quality of some studies and significant heterogeneity, such as marked differences in probiotic preparations, study populations, and outcome measures. (See <a class="local">'Clinical treatment studies using probiotics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical efficacy for treatment of allergic disease</strong> – There is no definitive evidence that prebiotics, probiotics, or synbiotics have efficacy in the treatment of any allergic conditions. Several meta-analyses suggest no benefit of probiotics in the treatment of eczema or asthma. Two meta-analyses reported a beneficial effect of probiotics in the treatment of allergic rhinitis, and studies evaluating prebiotics and synbiotics in the treatment of allergic disease show some promise. However, further studies are needed before any definitive conclusions can be drawn. (See <a class="local">'Clinical treatment studies using prebiotics'</a> above and <a class="local">'Clinical treatment studies using probiotics'</a> above and <a class="local">'Synbiotics for treatment of allergic disease'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911.</a></li><li><a class="nounderline abstract_t">West CE, Jenmalm MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: a wider perspective. Clin Exp Allergy 2015; 45:43.</a></li><li><a class="nounderline abstract_t">Lynch SV, Boushey HA. The microbiome and development of allergic disease. Curr Opin Allergy Clin Immunol 2016; 16:165.</a></li><li><a class="nounderline abstract_t">Ozdemir O. Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data. Clin Exp Immunol 2010; 160:295.</a></li><li><a class="nounderline abstract_t">Tang ML, Lahtinen SJ, Boyle RJ. Probiotics and prebiotics: clinical effects in allergic disease. Curr Opin Pediatr 2010; 22:626.</a></li><li><a class="nounderline abstract_t">Thomas DW, Greer FR, American Academy of Pediatrics Committee on Nutrition, American Academy of Pediatrics Section on Gastroenterology, Hepatology, and Nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 2010; 126:1217.</a></li><li><a class="nounderline abstract_t">Yao TC, Chang CJ, Hsu YH, Huang JL. Probiotics for allergic diseases: realities and myths. Pediatr Allergy Immunol 2010; 21:900.</a></li><li><a class="nounderline abstract_t">West CE, Jenmalm MC, Kozyrskyj AL, Prescott SL. Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward. Expert Rev Clin Immunol 2016; 12:625.</a></li><li><a class="nounderline abstract_t">Shibata R, Kimura M, Takahashi H, et al. Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants. Clin Exp Allergy 2009; 39:1397.</a></li><li><a class="nounderline abstract_t">Boženský J, Hill M, Zelenka R, Skýba T. Prebiotics Do Not Influence the Severity of Atopic Dermatitis in Infants: A Randomised Controlled Trial. PLoS One 2015; 10:e0142897.</a></li><li><a class="nounderline abstract_t">Liong MT. Safety of probiotics: translocation and infection. Nutr Rev 2008; 66:192.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Health Alert Network. Fatal gastrointestinal mucormycosis in an infant following ingestion of contaminated dietary supplement – Connecticut, 2014. http://www.bt.cdc.gov/han/han00373.asp (Accessed on November 25, 2014).</li><li><a class="nounderline abstract_t">Lee J, Seto D, Bielory L. Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008; 121:116.</a></li><li><a class="nounderline abstract_t">Michail SK, Stolfi A, Johnson T, Onady GM. Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2008; 101:508.</a></li><li><a class="nounderline abstract_t">Huang R, Ning H, Shen M, et al. Probiotics for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Cell Infect Microbiol 2017; 7:392.</a></li><li><a class="nounderline abstract_t">Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, et al. Probiotics for treating eczema. Cochrane Database Syst Rev 2018; 11:CD006135.</a></li><li><a class="nounderline abstract_t">Husein-ElAhmed H, Steinhoff M. Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis. J Dtsch Dermatol Ges 2023; 21:833.</a></li><li><a class="nounderline abstract_t">Kim K, Lee E, Kim M, et al. Therapeutic effectiveness of probiotics for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials with subgroup analysis. Asian Pac J Allergy Immunol 2023.</a></li><li><a class="nounderline abstract_t">Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy 2012; 42:112.</a></li><li><a class="nounderline abstract_t">Drago L, Iemoli E, Rodighiero V, et al. Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study. Int J Immunopathol Pharmacol 2011; 24:1037.</a></li><li><a class="nounderline abstract_t">Isolauri E, Arvola T, Sütas Y, et al. Probiotics in the management of atopic eczema. Clin Exp Allergy 2000; 30:1604.</a></li><li><a class="nounderline abstract_t">Brouwer ML, Wolt-Plompen SA, Dubois AE, et al. No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial. Clin Exp Allergy 2006; 36:899.</a></li><li><a class="nounderline abstract_t">Fölster-Holst R, Müller F, Schnopp N, et al. Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis. Br J Dermatol 2006; 155:1256.</a></li><li><a class="nounderline abstract_t">Grüber C, Wendt M, Sulser C, et al. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy. Allergy 2007; 62:1270.</a></li><li><a class="nounderline abstract_t">Viljanen M, Savilahti E, Haahtela T, et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005; 60:494.</a></li><li><a class="nounderline abstract_t">Sistek D, Kelly R, Wickens K, et al. Is the effect of probiotics on atopic dermatitis confined to food sensitized children? Clin Exp Allergy 2006; 36:629.</a></li><li><a class="nounderline abstract_t">Majamaa H, Isolauri E. Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997; 99:179.</a></li><li><a class="nounderline abstract_t">Weston S, Halbert A, Richmond P, Prescott SL. Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005; 90:892.</a></li><li><a class="nounderline abstract_t">Woo SI, Kim JY, Lee YJ, et al. Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome. Ann Allergy Asthma Immunol 2010; 104:343.</a></li><li><a class="nounderline abstract_t">Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 2012; 23:667.</a></li><li><a class="nounderline abstract_t">Adams CA. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev 2010; 23:37.</a></li><li><a class="nounderline abstract_t">Torii S, Torii A, Itoh K, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol 2011; 154:236.</a></li><li><a class="nounderline abstract_t">Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008; 159:1357.</a></li><li><a class="nounderline abstract_t">Yamamoto K, Yokoyama K, Matsukawa T, et al. Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with atopic dermatitis. J Dairy Sci 2016; 99:5039.</a></li><li><a class="nounderline abstract_t">Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr 2003; 36:223.</a></li><li><a class="nounderline abstract_t">Xiao JZ, Kondo S, Yanagisawa N, et al. Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin Exp Allergy 2006; 36:1425.</a></li><li><a class="nounderline abstract_t">Wang MF, Lin HC, Wang YY, Hsu CH. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol 2004; 15:152.</a></li><li><a class="nounderline abstract_t">Ishida Y, Nakamura F, Kanzato H, et al. Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study. J Dairy Sci 2005; 88:527.</a></li><li><a class="nounderline abstract_t">Helin T, Haahtela S, Haahtela T. No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study. Allergy 2002; 57:243.</a></li><li><a class="nounderline abstract_t">Tamura M, Shikina T, Morihana T, et al. Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial. Int Arch Allergy Immunol 2007; 143:75.</a></li><li><a class="nounderline abstract_t">Li L, Wen X, Gong Y, et al. HMGN2 and Histone H1.2: potential targets of a novel probiotic mixture for seasonal allergic rhinitis. Front Microbiol 2023; 14:1202858.</a></li><li><a class="nounderline abstract_t">Chen N, Liu F, Gao Q, et al. A Meta-Analysis of Probiotics for the Treatment of Allergic Airway Diseases in Children and Adolescents. Am J Rhinol Allergy 2022; 36:480.</a></li><li><a class="nounderline abstract_t">Zajac AE, Adams AS, Turner JH. A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis. Int Forum Allergy Rhinol 2015; 5:524.</a></li><li><a class="nounderline abstract_t">Dennis-Wall JC, Culpepper T, Nieves C Jr, et al. Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial. Am J Clin Nutr 2017; 105:758.</a></li><li><a class="nounderline abstract_t">Lue KH, Sun HL, Lu KH, et al. A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years. Int J Pediatr Otorhinolaryngol 2012; 76:994.</a></li><li><a class="nounderline abstract_t">Chen YS, Jan RL, Lin YL, et al. Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol 2010; 45:1111.</a></li><li><a class="nounderline abstract_t">Giovannini M, Agostoni C, Riva E, et al. A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis. Pediatr Res 2007; 62:215.</a></li><li><a class="nounderline abstract_t">Sadrifar S, Abbasi-Dokht T, Forouzandeh S, et al. Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial. Allergy Asthma Clin Immunol 2023; 19:1.</a></li><li><a class="nounderline abstract_t">Xie Q, Yuan J, Wang Y. Treating asthma patients with probiotics: a systematic review and meta-analysis. Nutr Hosp 2023; 40:829.</a></li><li><a class="nounderline abstract_t">Chang YS, Trivedi MK, Jha A, et al. Synbiotics for Prevention and Treatment of Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials. JAMA Pediatr 2016; 170:236.</a></li><li><a class="nounderline abstract_t">Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI. Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol 2010; 11:351.</a></li><li><a class="nounderline abstract_t">van der Aa LB, Heymans HS, van Aalderen WM, et al. Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial. Clin Exp Allergy 2010; 40:795.</a></li><li><a class="nounderline abstract_t">Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol 2012; 166:129.</a></li><li><a class="nounderline abstract_t">van de Pol MA, Lutter R, Smids BS, et al. Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics. Allergy 2011; 66:39.</a></li><li><a class="nounderline abstract_t">Faridzadeh A, Yadegari Y, Bakhshaee M, et al. The role of synbiotics as adjunctive agents in the treatment of allergic rhinitis: A randomized controlled trial. Health Sci Rep 2023; 6:e1571.</a></li></ol></div><div id="topicVersionRevision">Topic 13582 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12239261" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The effect of infections on susceptibility to autoimmune and allergic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24773202" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The gut microbiota and its role in the development of allergic disease: a wider perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26885707" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The microbiome and development of allergic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20345982" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Various effects of different probiotic strains in allergic disorders: an update from laboratory and clinical data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733491" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Probiotics and prebiotics: clinical effects in allergic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115585" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Probiotics and prebiotics in pediatrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20003066" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Probiotics for allergic diseases: realities and myths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26821735" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Probiotics for treatment and primary prevention of allergic diseases and asthma: looking back and moving forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508323" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical effects of kestose, a prebiotic oligosaccharide, on the treatment of atopic dermatitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571488" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prebiotics Do Not Influence the Severity of Atopic Dermatitis in Infants: A Randomised Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366533" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Safety of probiotics: translocation and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Safety of probiotics: translocation and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18206506" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19055205" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of probiotics in the treatment of pediatric atopic dermatitis: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28932705" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Probiotics for the Treatment of Atopic Dermatitis in Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30480774" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Probiotics for treating eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37345893" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Meta-analysis on preventive and therapeutic effects of probiotic supplementation in infant atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37578483" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Therapeutic effectiveness of probiotics for atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials with subgroup analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22092692" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22230409" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Effects of Lactobacillus salivarius LS01 (DSM 22775) treatment on adult atopic dermatitis: a randomized placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069570" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Probiotics in the management of atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16839405" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : No effects of probiotics on atopic dermatitis in infancy: a randomized placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17107398" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prospective, randomized controlled trial on Lactobacillus rhamnosus in infants with moderate to severe atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919141" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized, placebo-controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15727582" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650048" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Is the effect of probiotics on atopic dermatitis confined to food sensitized children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9042042" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Probiotics: a novel approach in the management of food allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15863468" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of probiotics on atopic dermatitis: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20408346" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of Lactobacillus sakei supplementation in children with atopic eczema-dermatitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23050557" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20403231" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The probiotic paradox: live and dead cells are biological response modifiers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20861645" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18795916" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Effects of nonpathogenic gram-negative bacterium Vitreoscilla filiformis lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27108169" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of prolonged ingestion of Lactobacillus acidophilus L-92 in adult patients with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12548058" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Probiotic bacteria in the management of atopic disease: underscoring the importance of viability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17083353" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15059192" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of perennial allergic rhinitis with lactic acid bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653517" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11906339" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : No effect of oral treatment with an intestinal bacterial strain, Lactobacillus rhamnosus (ATCC 53103), on birch-pollen allergy: a placebo-controlled double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17199093" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37869664" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : HMGN2 and Histone H1.2: potential targets of a novel probiotic mixture for seasonal allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35238209" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A Meta-Analysis of Probiotics for the Treatment of Allergic Airway Diseases in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25899251" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A systematic review and meta-analysis of probiotics for the treatment of allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28228426" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Probiotics (Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22513081" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20658483" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17597643" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A randomized prospective double blind controlled trial on effects of long-term consumption of fermented milk containing Lactobacillus casei in pre-school children with allergic asthma and/or rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36593510" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Immunomodulatory effects of probiotic supplementation in patients with asthma: a randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37073761" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treating asthma patients with probiotics: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26810481" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Synbiotics for Prevention and Treatment of Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20642296" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20184604" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21895621" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20716319" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Synbiotics reduce allergen-induced T-helper 2 response and improve peak expiratory flow in allergic asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37799445" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The role of synbiotics as adjunctive agents in the treatment of allergic rhinitis: A randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
